FORT LAUDERDALE, Fla., Aug. 14, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTC:OMCM.OB), one of the fastest growing companies in the EDC marketplace, today announced that its TrialMaster® EDC solution has been selected by a top 5 pharmaceutical company to run a 5 year late-phase, non-interventional oncology trial.
"We are pleased that this high profile organization, a leader in the oncology space, recognizes the high quality services that OmniComm provides and the innovations that our TrialMaster technology offers," stated Stephen Johnson, President and COO of OmniComm Systems. "Centralized monitoring with auto-redaction and an automated SDTM export utility were two of the key elements that secured our selection. We look forward to leveraging these innovative features to help drive down research costs and shorten study timelines."
The OmniComm TrialMaster EDC Suite is a comprehensive, functionally-rich solution to simplify clinical trial processes. Featuring proprietary, proven workflows, the TrialMaster system enables enhanced efficiencies and streamlined clinical operations across each stage of a trial. OmniComm's EDC solutions have been used in over 3800 clinical trials across the globe.
"While TrialMaster is an exceptional platform to run Phase II and III trials, we made conscious efforts to design it to be flexible enough to accommodate the needs of organizations as they structure late-phase studies as well," expressed Keith Howells, SVP of Development at OmniComm. "We look forward to executing this late-phase multi-center study with this key OmniComm client."
About OmniComm Systems
OmniComm Systems, Inc. ( www.OmniComm.com ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Dr Kuno van der Post OmniComm Systems, Inc. 954 473 1254
